- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Inhibikase Therapeutics, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| Fr | Inhibikase sees "opportunity" in cardiopulmonary disease for IkT-001Pro | 3 | Pharmaceutical Technology | ||
| Fr | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.04. | Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs | 1 | GlobeNewswire (USA) | ||
| 03.04. | Inhibikase Announces Pre-IND Meeting For IkT-001Pro | 1 | RTTNews | ||
| 03.04. | Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension | 163 | GlobeNewswire (Europe) | BOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor... ► Artikel lesen | |
| 02.04. | Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript | 2 | Insider Monkey | ||
| 01.04. | Earnings call: Inhibikase Therapeutics reports on Risvodetinib progress | 2 | Investing.com | ||
| 29.03. | Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 27.03. | Inhibikase Therapeutics GAAP EPS of -$3.57 misses by $0.82, revenue of $0.26M in-line | 1 | Seeking Alpha | ||
| 27.03. | Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity | 157 | GlobeNewswire (Europe) | BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor... ► Artikel lesen | |
| 27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics Inc expected to post a loss of 85 cents a share - Earnings Preview | 1 | Reuters | ||
| 07.03. | Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders | 2 | GlobeNewswire (USA) | ||
| 28.02. | Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro | 169 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor... ► Artikel lesen | |
| 07.02. | Inhibikase advances toward NDA for cancer drug IkT-001Pro | 2 | Investing.com | ||
| 07.02. | Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers | 146 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor... ► Artikel lesen | |
| 01.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.01. | Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib | 160 | GlobeNewswire (Europe) | Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD medications... ► Artikel lesen | |
| 17.01. | Inhibikase Therapeutics appoints Lees-Rolfe as CFO | 2 | Seeking Alpha |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,970 | -1,37 % | Bayer: Der nächste Meilenstein | Bayer hat in der Entwicklung einer Gentherapie zur Behandlung von Herzinsuffizienz einen bedeutenden Meilenstein erreicht. Die US-amerikanische Food and Drug Administration (FDA) der Therapie den Fast-Track-Status... ► Artikel lesen | |
| PFIZER | 24,530 | -0,06 % | Pfizer - mit Seagan soll die Wende kommen | ||
| GILEAD SCIENCES | 62,46 | -0,38 % | Virushepatitis bis 2030 eliminieren: Gilead Sciences fördert zahlreiche Projekte weltweit mit 4 Millionen US-Dollar - auch in Deutschland | Martinsried bei München (ots) - - Gilead vergibt 4 Millionen US-Dollar weltweit (ohne die Vereinigten Staaten) durch das Förderprogramm "ALL4LIVER Grant" -- Die World Hepatitis Alliance und hochrangige... ► Artikel lesen | |
| GSK | 19,020 | -0,89 % | EQS-News: CureVac gibt Start einer kombinierten Phase-1/2-Studie zur Vogelgrippe (H5N1) bekannt; Entwicklung in Zusammenarbeit mit GSK | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Studie
CureVac gibt Start einer kombinierten Phase-1/2-Studie zur Vogelgrippe (H5N1) bekannt; Entwicklung in Zusammenarbeit mit... ► Artikel lesen | |
| TEVA | 12,050 | -1,23 % | Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex | PETAH TIKVA (dpa-AFX) - The U.S. Supreme Court denied Vanda Pharmaceuticals Inc.'s (VNDA) petition for a writ of certiorari in its HETLIOZ Abbreviated New Drug Application litigation against... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 45,655 | -0,03 % | Novartis ernennt Ex-CEO von Bristol Myers Squibb als Board-Chef | DJ Novartis ernennt Ex-CEO von Bristol Myers Squibb als Board-Chef
ZÜRICH (Dow Jones)--Nach zwölf Jahren als Präsident des Verwaltungsrats tritt Jörg Reinhardt bei Novartis ab. Im Jahr 2025 wird... ► Artikel lesen | |
| MPH HEALTH CARE | 21,000 | +1,94 % | EQS-News: MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände | EQS-News: MPH Health Care AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände... ► Artikel lesen | |
| CRONOS GROUP | 2,310 | -0,52 % | Invafresh names Andrew Cron CDO | ||
| VIATRIS | 10,765 | -0,32 % | Viatris Announces Product Donations To Direct Relief of More Than 7 Million Doses of Medicine To Support Access to Medicine and Healthcare | Long-standing partnership with Direct Relief assists crisis areas around the worldSTEINHAUSEN, SWITZERLAND / ACCESSWIRE / April 19, 2024 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today... ► Artikel lesen | |
| HAEMATO | 17,200 | +1,18 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 17.04.2024 | The following instruments on XETRA do have their last trading day on 17.04.2024Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 17.04.2024ISIN NameDE000LB32W75 LBBW FZA 22/24DE000DW6C4A6... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 39,100 | -1,44 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
| BIONANO GENOMICS | 0,761 | 0,00 % | Bionano Genomics: Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping... ► Artikel lesen | |
| FSD PHARMA | 0,431 | -0,69 % | FSD Pharma Inc.: FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd | TORONTO, ON / ACCESSWIRE / April 22, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu")... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 9,600 | -1,98 % | Adhoc: Spexis AG: Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera | Spexis AG / Key word(s): Miscellaneous
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of... ► Artikel lesen | |
| CSPC PHARMA | 0,725 | +2,23 % | CSPC Pharmaceutical Group-Aktie kann Vortagsniveau nicht halten (0,686 €) | Im Minus liegt zur Stunde die Aktie der CSPC Pharmaceutical Group . Das Wertpapier kostete zuletzt 0,69 Euro. An der Börse liegt die CSPC Pharmaceutical Group-Aktie aktuell im Minus. Die Aktie verbilligte... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +6,72 % bei einem Aktienkurs von 1,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
